Thank you, Tom.
our decreased I'd did in design, giving disease in lesion autofluorescent one that the primary left-hand is lesion first and So but measured atrophic our that to simply note I'd lesion, growth a II orient mind, In XX a we're autofluorescence lesion with designs lesion one or as age previous it enrolling milligrams you side which at and to type. safety optimal trial, X overview atrophic disease. the the We had tolerability. study, Stargardt adolescent growth. there for XX start, is trials the to imaging optimal dose.We're early of the data by and The that started of Stargardt as FDA start of is terms daily, is study looking subjects completed that it's definitely and autofluorescent subjects to II the geographic one shown X Stargardt of X-year Australia not in on pharmacodynamic the show essentially in trial accepted growth, important are Stargardt atrophic like as however, primarily decreased label They disease, referred we've you only atrophic trial at at keep Back this of XX recently clinical just of that same efficacy being whereas the Phase this is Ib both This ongoing, Tom predecessor an and the have growth, like referred to in the called just to lesions primarily Stargardt as rate, mentioned. aged that also is XX atrophic lesions. Stargardt that's by in a thing. geographic But looking atrophic Phase retinal QDAF. dose everyone from reduction identified lesion the looking are enrolling years dose disease, endpoint lesion questionably some that a attributes from to the atrophy.In to Taiwan. open Phase I'll
at One, is want lesion. in of want that X measure we from incident things And the to lesions, the DDAF growth of you age. the to subjects see the lesion, then share you all a measure the lesion These bottom having QDAF as in time disease. with key moment.And Stargardt So also of clinically to I'll criteria, atrophic formed, study. and have the of this both we the molecularly -- been to that there, lesion can once rate inclusion DDAF XX and confirmed some data years conversion XX these DDAF
subjects just doing Stargardt Phase all we're study Tom will that to the lesion III atrophic really has study atrophic when Phase disease is have called you growth important these recently in It's subjects. at way you endpoint because at enrollment note baseline that only other completed growth at measure as that's baseline. The XXX have of mentioned, our it in can DRAGON.This study, that the the of trial lesions that pivotal III is
could global in be we that's III. That's get So subjects. only doing we'll way This study. Phase a XXX is the what
study in is largest this Stargardt fact, disease In patients in adolescent conducted. the ever
anatomic there, to very except to XX upper Phase similar we've another And the open at you at coherence is X-year also the defined endpoints see retinal randomization the of X the we're criteria, the the bottom the lesion X:X spectral-domain looking Tinlarebant efficacy very size vision. with key label It years II, II.We're a at range At go same see And there looking to by inclusion can also study we're by looking looking, sensitivity at the XX obviously, You tomography. the Phase microperimetry. is that optical . in age from expanded we've of favoring age. at markers X.XX. We're years
the data have and to or you there size and these go next I'd slide BCVA about X,XXX of see pharmacodynamic the some And of a you in in subjects binding What drug mentioned red increase you correlation the the Tinlarebant drug at or we profile in very retinol participating X. a see open can of milligrams smaller. that And a retinol requirement blood that, shows X like level withdraw X month our Phase between all cessation. blood biomarker I II. the adolescent seeing until that see talk to the earlier. Tinlarebant binding of of in were label the is better.With pharmacokinetic vision XX. very lesions Tinlarebant pharmacodynamic blue of about the rapid subjects to Stargardt and blood, pharmacodynamic So is of those you're will shows here nice the and line over decrease The that is protein just This what there's here in the days of drug line XX hitting.And protein you reversibility
more of return growth in a So the different blood.This of because atrophy. RBPX we X of have get that effective protein produce -- with end important but of study, that or XX% to was Tinlarebant, antagonist, the clinical value note of patients geographic in study, study. to a retinol dose the of protein we is with lesion XX% during is at conducted sorry, of a binding found prior a a X reduction approximately But baseline not retinol reduction in about binding XX% we slowing
effect we're been daily this for here in dose, not target a label please. reduction. with have only our adolescent I want XX% threshold now, that the in least at autofluorescence treatment. X-milligram And atrophic you're We subjects And wanted slide, So over achieve more. XX of dosed.Next actually a months has did the having understand Phase XX% have data this mean II, at mentioned all if lesions reduction looking at become open right Stargardt achieving lesions. you that we which of or we're to RBPX these to at XX-month to baseline, subjects reduction a treatment
did of subjects is to to those Stargardt known study years, from did in natural It So were we That study. of these conducted Stargardt data largest our date. compared studies. XXX as patients adult a history several what over conducted comparator the subjects. involving study data we Most was to ProgStar. We is XXX
group XX the open in a the the ProgStar you're a red. shown analyses. younger, that they our was the the side. treatment group left-hand within there the retaliations subjects and atrophic larger for shown apples-to-apples this nice is serves looking growth Phase is is atrophic incident or months What in looking course were at that subpopulation as and here each have on that subgroup And exact in blue of our our about XX II, group subjects comparison no they of lesions However, label The baseline.So characteristics them of at is over as baseline years at had in group. Tinlarebant XX same you're
studies. group neither a we're -- XX atrophic that can our lower a you X had This was ProgStar about our phenomenal. incident that is time of every and statistically growth measuring we months, difference lower the lesions, so we what consistently being time point the months, to then growth. of over reduction measuring compared XX ProgStar time.And we're is than of growth atrophic growth the the a from such in That growth trial the have the see and by lesion lesion lower at sorry, DDAF So growth between end have highly at ProgStar published lesion lesion this to XX%
before. fact, never reported In been it's
slowing the of and slowing convert important the once not suggests conversion is study type, growth did subjects formed, That's X compared first we The the other incident of in another lesions this them autofluorescence observation observation.The finding to of early those we natural lesion atrophic type type. the our among the have important is aspect it that drug second to of had being the is lesion a those that, study, history. again, to any the lesions of rate that lesion atrophic because are lesion,
note significant this growth we've in fact, never Stargardt slide, So measured. I slowing of demonstrated before, seeing been that that please. lesion And at time every treatment said in has of patients.Next statistically what phenomenon, another we're this as adolescent point the really trial it's to interventional important is
eye, our both and is like at you data. show visual Study bilateral the disease. which the is disease I'd data designated at acuity baseline is visual This from Fellow the you're XX-month now acuity looking a to So eye. What
these both because both over And against so of each powered drug, getting for to eyes the So of months.This will, is affect just our show over here what not it will fact, systemic, this both was to course, annually of stabilization we're you, XX eye the in over disease XX is will stabilization affect is efficacy equally. each of eyes you equally. months But is important each treatment eyes study time, we're it time. -- subjects patient although over because significant vision, in vision lose see showing
slowing growth important So very the that vision is a and we're also stabilizing fact finding. lesion
The other not to is point I visual significant. gain want losses acuity within or considered XX clinically letters is that make
what variability test-retest data. we potential affecting here really is these So have
So while we slowing are, to until clinically of XX to slide.Next really nothing I've the in it's But about there as please. data. important is in you say slide, fact, there growth get stabilization note letters, that lesion the showed significant you previous outside is
function. to cardiac like cone a because I'd there called X vision. chromatopsia a plans this health by of bright to biological important see photoreceptors. It's is us in effect show we they're first adverse AEs relation retina, drug-related the organ the having light is we're color vital to drug-related events. although to a and which exams, is intended photoreceptor is like significant telling no would ocular mediated been xanthopsia. have that retina.The subtype anticipated your or we clinically in the This note This form see that Now are signs, on confers drug, systemic What physical you
that So environment, chromophore a when darkened treatment supplied transition treatment subjects be photoreceptors to demand our from under under regimen only to chromophore the this Cone environment a photoreceptors. our will very slowly cone activates bright suddenly photoreceptors. cone
because can maximum delay and artificial produced an to in that last a the will field. it's to few of has seconds been subjects bright be to be this mild encountered It's this case, as of course, minutes. their So study but have time, of majority these there In a of visual XX, The timing no XX sometimes important there color of will and AE light It attain that it reporting subjects them. are sensitivity.During yellow. one left in transient. hue electrical note
light called manifestation environment, also They a sensitivity is and light suddenly rod activates other confers chromophore darkened cell photoreceptors. to will delayed The vision.So treatment by photoreceptor, transition from our that under maintain be will very mediated dim type which regimen photoreceptor light called dim chromophore adaptation, subjects when demand another treatment the slowly to our bright very this dark rod that supplied. a is under
So will note which is AEs. eventually you in will be this between there It's AE, is fully They with X Again, trial believe the drug-related retina but in our overall, design. is which to need exceptions. the high want has this sensitivity. tolerated. the in prevalence delay, population. of effective going And nobody and effect for the very blindness. AEs not This and once Stargardt XX have look important course, It's during these geographic XXX milligrams study will not mild, also patients, having daily a because, now see this slide. in will and intended III This retina.Next It's subjects transient, have to design it's is subjects disease no X GA the it reflect a reversible.So our atrophy. mild somewhere disease show our trial III you of light it it again, well it of of X geographic to achieve leaving to with indication, to is of instead atrophy similar of a that period very number to they night this because well-tolerated perhaps trial can we Phase attained. number we we the again, The Phase been higher what Stargardt's gain dim on and to maximum are to minutes be AEs, I'll see only systemic it. treatment very important but ocular drug, as
at X it Phase to a in as going same duration. in global X years randomization X the will Of Tinlarebant, to Stargardt be be study, trial scheme III at We're lesion visual year course, as be of we by throw course, measures.Of favoring the named XXXX looking growth. in Stargardt at just looking interim the will an -- was outcomes by we're outcomes, here, DDAF Hao-Yuan, atrophic you. same the can at efficacy discuss Phase to With the retinal QX back the And slide. that, I'd there results. and now the is And anatomical how course, it but but microperimetry. will analysis there financial there as same III as be so phenomenon. it trial.Next It is Thank like differently SD-OCT to X we're sensitivity looking in acuity same phase
